[18F]JNJ-64511070

[18F]JNJ-64511070 is a fluorine-18 labeled positron emission tomography (PET) radiopharmaceutical developed by Janssen Research & Development for the visualization and quantification of Tau protein aggregates in the brain. Tau pathology, characterized by the formation of neurofibrillary tangles, is a key biomarker for Alzheimer's disease and other tauopathies, correlating strongly with neurodegeneration and cognitive impairment. As a second-generation Tau tracer, [18F]JNJ-64511070 is designed to provide high binding affinity and selectivity for Tau over other protein aggregates like amyloid-beta, with favorable brain kinetics and low off-target binding. Clinical studies have focused on evaluating its dosimetry and kinetic profile in healthy individuals and patients with Alzheimer's disease to support its use as a diagnostic tool and biomarker in drug development.